Rendón-García H, Covarrubias-Espinoza G, Noriega-Acuña B

Language: Spanish
References: 19
Page: 2-7
PDF size: 46.62 Kb.

ABSTRACT

Background: Febrile neutropenia in cancer patients is recognized as one of the most important complications of chemotherapy in terms of morbidity and mortality, infections being the main consequence of it. Objective: To determine the association of infectious with high risk factors for severe neutropenia (CNT ‹1,000 cells/mm³) with fever in patients with acute lymphoblastic leukemia.
Methods: Transversal study in patients with LAL admitted with high-risk criteria of neutropenia with fever, clinical variables and risk factors were analyzed in febrile neutropenia withChi-square test. Dichotomous analysis by logistic regression odds ratios was evaluated in the program NCSS 0.7. P ‹0.05 values were considered significant for statistical test. The project was endorsed by the Ethics Committee of the institution in which they are performed.
Results: We reviewed 84 patients of whom 44 (53%) were male. The main infectious comorbidity was related to respiratory processes and septic shock in 38%. Severe infectious comorbidity occurred in 61 (72%) subjects. Grade III Neutropenia occurred in 55 (65.50%) cases, similar than duration of neutropenia › 5 days. The logistic regression analysis showed significance for neutropenia › 5 days in cases with severe comorbidity (OR 0.14), and leukemia in relapse (RM 24.10).
Conclusions: In acute lymphoblastic leukemia with severe infection and neutropenia at high risk should be assessed neutropenia judgment for better control of infectious comorbidity.

REFERENCES

1. Arnello M, Quintana J, Barraza P. Neutropenia febril en niños con cáncer en un centro asistencial en Santiago, Chile. Revista chilena infectología. 2007; 24(1): 27-32.

2. Tello O, Rivera R. Morbimortalidad por infección en el niño con cáncer. Boletín Clínico Hospital Infantil del Estado de Sonora. 2002; 19: 51-6.

3. Hakim H, Flynn P, Knapp K. Etiology and clinical course of febrile neutropenia in children with cancer. Journal Pediatric Hematology Oncology. 2009; 31(9): 623-9.

4. Alexander S, Wade K, Hibberd P, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. Journal of Pediatric Hematology Oncology.2002; 24(1): 38-42.

5. Hughes W, Armstrong D, Bodey G, et al. 2002 Guidelines for the use of antimicrobial agents in neutropénico patients with cancer.2002; 34: 730-51.

6. Porto P, Braga K, De Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. Journal Pediatric Hematology Oncology.2006; 28(10): 665-70.

7. Talcott J, Siegel R, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, twocenter validation of a prediction rule. Journal of Clinical Oncology.1992; 10(2): 316-22.

8. Ammann R, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kuhne T, Popovic M, Luthy A, and Aebi C, Predicting Adverse Events in Children With Fever and Chemotherapy-Induced Neutropenia: The Prospective Multicenter SPOG 2003 FN Study. 2010; 28(12): 2008-14.

9. Santolaya AM, Alvarez A, Becker J. Cofré, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer neutropenia and fever. Journal of clinical oncology. 2001; 19(14): 3415-21.

10. Portugal R, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients base on the area over the neutrophil curve. Journal of Clinical Oncology. 2009; 27(23): 3849-54.

11. Ravaud A, Chevreau C, Cany L, et al; Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropénico chemotherapy regimens: Results of a randomized phase III trial. Journal of Clinical Oncology. 1998; 16(9): 2930-6.

12. Dufort G. Guía para el tratamiento del paciente con neutropenia febril. Archivos pediátricos de Uruguay. 2009; 80(1): 37-41.

13. Pizzo PA, Poplack D. Principles and practice of Pediatric Oncology. Fifth Edition. Lippincott Williams and Wilkins; Philadelphia, USA 2006: 1269-320.

14. Contreras MR. Tesis Fiebre en el paciente oncológico. Hospital Infantil del Estado de Sonora. 2001.

15. Freifeld AG, Walsh TT, Marshall DD, et al; Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. Journal of Clinical Oncology. 1995; 13(1): 165-76.

16. Mustafa MM, Carlson L Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatric Infect Disease Journal.2001; 20(3): 362-9.

17. Sierrasesúmaga L, Antillón Klussman. Tratado de Oncología Pediátrica. Enfermedades malignas del niño y del adolescente. Pearson educación, S.A. Madrid 2006: 755-80.

18. Valle P, Land M, Santoro G. Predictive model for the length of hospital stay of children with hematologic malignancies, neutropenia, and presumen infection. Journal Pediatric Hematology Oncology. 2004; 26(12): 813-6.

19. Wiley J, Smith N, Leventhal B, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during chemotherapy: A multivariate analysis of risk factors. Journal of clinical oncology. 1990; 8(2): 280-6.